Compare FF & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | LUCD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 192.9M |
| IPO Year | 2005 | 2021 |
| Metric | FF | LUCD |
|---|---|---|
| Price | $5.47 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 358.3K | ★ 813.2K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | N/A | $115.58 |
| Revenue Next Year | N/A | $130.54 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $3.09 | $0.81 |
| 52 Week High | $6.99 | $1.63 |
| Indicator | FF | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 28.28 |
| Support Level | $5.06 | N/A |
| Resistance Level | $5.55 | $1.07 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 51.78 | 4.77 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.